FDA to decide on Qnexa obesity drug in July

US regulators will decide in July whether to approve Qnexa, the first obesity drug in more than a decade, extending the initial deadline by three months, the California-based drug-maker VIVUS said.

The extra time is a "standard extension period" offered by the in order to review additional risk management strategies that were submitted by the company, said a statement issued late Monday.

The new date for a decision is now set for July 17.

An advisory panel to FDA in February urged approval of Qnexa, after warning against its approval in 2010 due to safety concerns.

The panel voted 20-2 that the FDA should allow Qnexa on the market, saying the latest overall benefit-risk assessment supported its approval, but asking for more data on potential risks and how to avoid them.

For instance, some people who took high doses of the drug experienced increased heart rate. When taken by pregnant women it also boosted the risk of having a baby with .

"The Qnexa REMS (risk evaluation and mitigation strategy) submission is comprehensive, with materials based on ongoing feedback from the FDA since our advisory committee meeting in February," said Leland Wilson, of VIVUS.

"We look forward to finalizing our REMS with the FDA while we move forward with our commercialization plans."

combines two existing drugs, the appetite suppressant phentermine and topiramate, an anti-convulsant that can be used in conjunction with other drugs for weight loss.

Some doctors already prescribe the combination as an off-label use for helping patients manage their weight.

Studies have shown dieters could lose up to 10% of their weight when taking the drug, along with regular exercise and following a healthy diet.

The FDA does not have to follow the advice of the advisory panel, though it usually does.

add to favorites email to friend print save as pdf

Related Stories

FDA rejects new obesity drug Qnexa

Oct 30, 2010

The US Food and Drug Administration has rejected a marketing request by Vivus for its new obesity treatment called Qnexa, because it considers it a health risk, the California-based biotech firm said in a statement.

FDA panel backs previously rejected obesity pill

Feb 22, 2012

(AP) -- A panel of advisers to the Food and Drug Administration overwhelmingly backed approval for a highly anticipated anti-obesity pill called Qnexa, a drug which the FDA previously rejected due to safety concerns.

Vivus weight loss drug faces FDA panel this week

Jul 13, 2010

(AP) -- Vivus Inc.'s experimental drug Qnexa was effective in cutting weight, the Food and Drug Administration said Tuesday, while acknowledging lingering concerns over the drug's nervous system and psychiatric side effects.

FDA rejects highly-anticipated diet drug Qnexa

Oct 29, 2010

(AP) -- Federal health regulators have decided not to approve an experimental diet pill called Qnexa, which had been touted by many experts as the most promising weight-loss drug in more than a decade.

Experimental drug achieves unprecedented weight loss

Apr 11, 2011

An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments